Amicus Therapeutics, Inc. (FOLD) Holdings Increased by Moors & Cabot Inc.

Moors & Cabot Inc. boosted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 84.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,100 shares of the biopharmaceutical company’s stock after buying an additional 10,550 shares during the period. Moors & Cabot Inc.’s holdings in Amicus Therapeutics were worth $320,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its holdings in shares of Amicus Therapeutics by 374.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,098,083 shares of the biopharmaceutical company’s stock valued at $10,518,000 after purchasing an additional 866,793 shares during the period. Vanguard Group Inc. increased its holdings in shares of Amicus Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,807,772 shares of the biopharmaceutical company’s stock valued at $203,205,000 after purchasing an additional 541,308 shares during the period. Sofinnova Investments Inc. increased its holdings in shares of Amicus Therapeutics by 51.3% in the 4th quarter. Sofinnova Investments Inc. now owns 674,636 shares of the biopharmaceutical company’s stock valued at $6,462,000 after purchasing an additional 228,667 shares during the period. Xact Kapitalforvaltning AB increased its holdings in shares of Amicus Therapeutics by 15.7% in the 4th quarter. Xact Kapitalforvaltning AB now owns 33,841 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 4,600 shares during the period. Finally, Emory University increased its holdings in shares of Amicus Therapeutics by 7.5% in the 4th quarter. Emory University now owns 217,874 shares of the biopharmaceutical company’s stock valued at $2,087,000 after purchasing an additional 15,148 shares during the period.

Several brokerages recently commented on FOLD. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, February 26th. BidaskClub cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the company a “buy” rating in a research note on Monday, April 22nd. Finally, ValuEngine cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $18.19.

Shares of NASDAQ FOLD opened at $12.07 on Tuesday. The company has a market capitalization of $2.88 billion, a P/E ratio of -9.08 and a beta of 1.79. Amicus Therapeutics, Inc. has a 52 week low of $8.27 and a 52 week high of $17.62. The company has a debt-to-equity ratio of 0.94, a current ratio of 6.40 and a quick ratio of 6.30.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.09). The company had revenue of $34.00 million for the quarter, compared to the consensus estimate of $37.82 million. Amicus Therapeutics had a negative return on equity of 64.58% and a negative net margin of 386.18%. The firm’s quarterly revenue was up 103.6% compared to the same quarter last year. As a group, equities analysts forecast that Amicus Therapeutics, Inc. will post -1.16 earnings per share for the current year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $13.51, for a total transaction of $270,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jay Barth sold 70,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $12.52, for a total value of $876,400.00. Following the sale, the insider now directly owns 156,037 shares of the company’s stock, valued at approximately $1,953,583.24. The disclosure for this sale can be found here. Insiders have sold 180,000 shares of company stock valued at $2,401,200 in the last ninety days. Company insiders own 2.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/14/amicus-therapeutics-inc-fold-holdings-increased-by-moors-cabot-inc.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Read More: How to Invest in a Bull Market

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.